Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dietary elimination plus omeprazole versus omeprazole alone for pediatric eosinophilic oesophagitis
ACTRN12613001210763Phase 3Recruiting
- Sponsor
- Murdoch Children's Research Institute
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of omeprazole in eosinophilic esophagitis (EoE) (2 arms), sponsored by Murdoch Children's Research Institute. Primary endpoint: Histological remission of eosinophilic oesophagitis. Started Aug 2012; status: recruiting.
02
Drugs
omeprazole
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on ACTRN12613001210763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001210763.